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Abstract
Background: Within the human placenta, the cytotrophoblast consists of a proliferative pool of
progenitor cells which differentiate to replenish the overlying continuous, multi-nucleated
syncytiotrophoblast, which forms the barrier between the maternal and fetal tissues. Disruption to
trophoblast differentiation and function may result in impaired fetal development and preeclampsia.
Caspase-14 expression is limited to barrier forming tissues. It promotes keratinocyte
differentiation by cleaving profilaggrin to stabilise keratin intermediate filaments, and indirectly
providing hydration and UV protection. However its role in the trophoblast remains unexplored.
Methods: Using RNA Interference the reaction of control and differentiating trophoblastic BeWo
cells to suppressed caspase-14 was examined for genes pertaining to hormonal, cell cycle and
cytoskeletal pathways.
Results: Transcription of hCG, KLF4 and cytokeratin-18 were increased following caspase-14
suppression suggesting a role for caspase-14 in inhibiting their pathways. Furthermore, hCG, KLF4
and cytokeratin-18 protein levels were disrupted.
Conclusion: Since expression of these molecules is normally increased with trophoblast
differentiation, our results imply that caspase-14 inhibits trophoblast differentiation. This is the first
functional study of this unusual member of the caspase family in the trophoblast, where it has a
different function than in the epidermis. This knowledge of the molecular underpinnings of
trophoblast differentiation may instruct future therapies of trophoblast disease.
Background
Chorionic villi protrude into the maternal tissue to form a
bi-directional barrier with a large surface area for
exchange between the maternal and fetal circulations.
These villi are covered by cells of the two layers of the tro-
phoblast, the inner cytotrophoblast and overlying syncy-
tiotrophoblast. The cytotrophoblast provides the
proliferative pool of cells to fuse with and replenish the
overlying syncytiotrophoblast, which is appositional with
the maternal circulation. The syncytiotrophoblast is a con-
tinuous multinucleated syncytium which structurally and
functionally separates the maternal circulation from the
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fulfils hormonal and endothelial functions and protects
the fetus against maternal pathogens [Reviewed in [1]].
Caspase-14 is an unusual caspase expressed in remarkably
few tissues, most of which form a barrier between two
privileged environments indicating a conserved role in
barrier formation [2]. Its characterisation has been best
explored in the epidermis where it indirectly modulates
corneocyte intermediate filament stability, hydration,
water balance and UV-B protection during keratinocyte
differentiation through its cleavage of filaggrin [3-6].
However very little attention has been given to caspase-14
in the human trophoblast, although it is present in the
placenta [7] and in BeWo cells [8].
Keratinocyte differentiation and barrier formation is
dependent on the expression of the Krüppel-Like Factor 4
(KLF4) transcription factor [9-11], which regulates the
transcription of cyclin-D2 by binding to its promoter
region, leading to cell cycle arrest at the G1/S-phase
boundary [12]. It has been noted that KLF4 contains a
potential binding motif (YHCD) for caspase-14 [13] and,
given the role of both proteins in keratinocyte differentia-
tion and that of KLF4 in the maintenance of the human
placenta [14,15], it is attractive to speculate a synergy
between the two in trophoblast barrier formation.
The cytoskeletal trophoblast marker cytokeratin-18 is
cleaved during trophoblast apoptosis, resulting in the
destabilisation of the cell architecture and apoptotic vesi-
cle formation [16,17]. Cytokeratin-18 is a key intermedi-
ate filament protein in the trophoblast; the expression,
structure and localisation of which remains plastic to
modulate the cytoskeletal arrangement in response to a
multitude of cell processes. In particular, trophoblast dif-
ferentiation requires extensive cytoskeletal rearrangement
to prepare and exact syncytialisation. That caspase-14
modulates keratin filament stability in the epidermis sug-
gests the potential for a conserved function of caspase-14
in cytoskeletal regulation during barrier formation.
The BeWo cell line was derived from a tumour of the
cytotrophoblast known as a choriocarcinoma [18]. Many
aspects of trophoblastic growth, differentiation, metabo-
lism and hormone production are observed in this cell
line [18]. We have previously shown that BeWo cells
treated with 20 micromolar (μM) Forskolin undergo bio-
chemical differentiation similar to that of the human tro-
phoblast, characterised by increased hCG production,
after 24 and 48 hours of treatment [8]. We demonstrated
that caspase 14 was expressed in these cells. Meanwhile,
morphological differentiation, characterised by reduced
and diffuse E-cadherin expression symbolising intercellu-
lar fusion, is commenced at 48 hours and well established
by 72 hours of treatment [8]. Therefore, 24 hours incuba-
tion represents early biochemical differentiation, 72
hours represents morphological differentiation, while 48
hours represents the switch between biochemical and
morphological differentiation. As such, it is the cell line
most representative of in vitro trophoblast differentiation
and the model used throughout this paper.
Methods
All relevant ethical guidelines have been strictly adhered
to. BeWo cells were obtained from the American Type
Culture Collection (ATCC) and maintained in growth
media containing 5% fetal bovine serum (FBS) and 0.5%
penicillin/streptomysin in Hams F12K. For treatment,
cells were seeded at a density of 2.5 × 105 cells/ml and
grown for 8 hours at 37°C and 5% CO2.
RNA interference (RNAi)
RNAi was conducted by delivering 100 nM of caspase-14
short interfering ribonucleic acid (siRNA) (Invitrogen,
Cat. No.1299003) into the cells using Lipofectamine2000
(Invitrogen, Cat. No. 11668) diluted in OptiMEM (Gibco,
Cat. No. 31985) as the transfection agent, and incubated
for 16 hours. Following this, the growth media was
changed for 20 μM Forskolin to induce biochemical and
morphological differentiation [19,20], with dimethyl sul-
foxide (DMSO) used for normal cycling controls.
Quantitative real time reverse transcriptase polymerase 
chain reaction (RT-PCR)
RNA was extracted using the TriReagent method [21].
Briefly, supernatant debris and adherent cells were col-
lected and treated with 500 μl TriReagent (Sigma, Cat. No.
T942) and 200 μl chloroform added. Samples were spun,
the upper aqueous phase collected and isopropanol
added. After overnight precipitation at 4°C, samples were
spun, washed with 75% ethanol and resuspended in
RNase-free H2O. RNA (2.1 μg) was treated with DNase
(Promega, Madison, USA) before undergoing reverse tran-
scription (RT) by heating to 25°C for 10 minutes, 55°C
for 50 minutes and 70°C for 15 minutes. Following this,
cDNA were stored at -20°C until required.
Five microlitres of SybrIQ (BioRad, Hercules, USA) mixed
with 1 μl of each primer, 2 μl dH2O and 1 μl cDNA was
used for all quantitative Real Time RT-PCR (Reverse Tran-
scriptase Polymerase Chain Reaction) reactions con-
ducted. Primers for the homo sapiens mRNA species used
are listed in Table 1. Each reaction was denatured at 95°C
for 3 minutes and subsequently cycled 40 times at 95°C
for 1 second, 60°C for 15 seconds and 72°C for 5 sec-
onds, except for L19, which was annealed at 51°C. Melt
analysis was then conducted by raising the temperaturePage 2 of 10
(page number not for citation purposes)
Reproductive Biology and Endocrinology 2009, 7:98 http://www.rbej.com/content/7/1/98from 72°C to 99°C at 0.5°C intervals for 3 minutes to
ensure accumulation of the desired product. All PCR data
obtained were standardised against the expression of L19.
Western blot analysis
Protein was extracted from cells using Radioimmunopre-
cipitation (RIPA) buffer containing 150 mM NaCl, 50
mM Tris-HCl, pH 7.5, 1% Triton X-100, 0.5% sodium
deoxycholate, 0.1% SDS, and 0.1 mM Phenylmethylsulfo-
nyl fluoride (PMSF). The amount of protein was esti-
mated using the Bradford assay [22]. Ten micrograms of
protein was denatured by heating to 95°C for 5 minutes
prior to separating using 12% sodium dodecyl sulfate
polyacrylamide gel electrophoresis (SDS-PAGE), then
transferred to a nitrocellulose membrane and blocked
with 5% milk powder in 0.05% TBS-T and incubated with
the relevant primary antibody in TBS-T overnight at 4°C
(Table 2). Membranes were washed in TBS-T and incu-
bated for 90 minutes with a goat anti-mouse IgG
(1:10,000) (Sigma, Cat. No. A3688), washed with TBS-T
and developed with SuperSignal West Pico Chemilumi-
nescent Substrates (ECL) (Pierce, Cat. No. 34080) as per
manufacturer's instructions. Membranes were photo-
graphed using a Kodak ImageStation.
Following imaging, the antibodies were removed from the
membranes (DMSO/Forskolin treated; RNAi with DMSO;
RNAi with Forskolin) using a Stripping Buffer composed
of 1% β-mercaptoethanol in TBS-T for 30 minutes. Mem-
branes were then re-probed with different antibodies to
assess protein expression from the same samples. Mem-
branes were reprobed up to 4 times.
Statistical significance for all experiments was determined
using One Way Analysis of Variance (ANOVA) t-tests
using Microsoft Excel, with statistical significance estab-
lished as achieving a P-value less than 0.05 (P < 0.05). All
experimental groups within this paper contained 6 repli-
cates, and no results were excluded in the preparation of
the data. Bar graphs show the Mean +/- the Standard Error
of the Mean (s.e.m.).
Results
BeWo cell differentiation
Caspase-14 mRNA expression was reduced at all time
points following Forskolin treatment (P < 0.05) (Fig. 1A)
and caspase-14 protein was also found to be significantly
reduced 48 and 72 hours after Forskolin treatment, coin-
ciding with morphological differentiation (P < 0.05) (Figs
1B, C). Our previous studies had shown a fall in caspase
14 mRNA expression with Forskolin, but the timed con-
trols had also shown a concomitant and greater fall, and
an increase in protein levels after 24 hours of differentia-
tion [8]. This may be explained by the disparity between
the antibodies used, the antibody in the present study
being the same as has been extensively used in studies of
the epidermis [3,6,23,24]. Interestingly however, cleavage
of caspase-14 into its constituent subunits, while observed
in the positive control skin sample, was not detected in
any BeWo cell extracts regardless of Forskolin treatment
Table 1: Primers for the homo sapiens mRNA species used
Primer Accession Number Primer Sequence Size
Caspase-14 NM_012114 Forward 5'-tgcacgtttattccacggta-3'
Reverse 5'-tgctttggatttcagggttc-3'
204 bp
Filaggrin NM_002016 Forward 5'-ggcaaatcctgaagaatcca-3'
Reverse 5'-tgctttctgtgcttgtgtcc-3'
187 bp
Keratin-18 NM_000224 Forward 5'-cacagtctgctgaggttgga-3'
Reverse 5'-gagctgctccatctgtaggg-3'
164 bp
KLF4 NM_004235 Forward 5'-cccacacaggtgagaaacct-3'
Reverse 5'-atgtgtaaggcgaggtggtc-3'
169 bp
L-19 NM_000981 Forward 5'-ctgaaggtcaaagggaatgtg-3'
Reverse 5'-ggacagagtcttgatgatctc-3'
194 bp
β-hCG NM_001009050 Forward 5'-gcaccaaggatggagatgtt-3'
Reverse 5'-gcacagatggtggtgttgac-3'
173 bp
Table 2: Antibodies used for the detection of proteins via Western blotting
Target Source Species Size (kDa) Dilution
Caspase-14 Wim Declercq, Ghent, Belgium rabbit 29, 20, 18.5 1:2500
β-hCG Dako; A0231 rabbit 28 1:6000
KLF4 Zymed Labs; 42-4100 rabbit 58 1:5000
Keratin-18 Calbiochem; AP1021 rabbit 44 1:5000
GAPDH Invitrogen; 39-8600 mouse 42 1:5000Page 3 of 10
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the human trophoblast, or is rapidly turned over and
present at undetected levels.
Synthesis and production of hCG was significantly
induced in BeWo cells by the addition of Forskolin at all
time points, confirming the successful initiation of bio-
chemical differentiation (P < 0.05) (Figs 1D-F). Therefore,
Forskolin induces BeWo cell differentiation consistent
with the human trophoblast.
The cell cycle suppressing transcription factor KLF4 is
transcriptionally elevated during BeWo cell differentia-
tion (P < 0.05) (Fig. 1G), suggesting that it is involved in
cell cycle withdrawal preceding differentiation. However,
Western blot analysis revealed no change in KLF4 protein
expression aside from being reduced after 48 hours of For-
skolin treatment (P < 0.05) (Figs 1H, I). This implies that
while KLF4 transcription is enhanced it is not being trans-
lated into protein at nearly the same rate, or that KLF4
protein turnover is elevated. The mechanism responsible
BeWo cell differentiation effects gene transcriptionFigure 1
BeWo cell differentiation effects gene transcription. The effect of Forskolin treatment on BeWo cell expression of (A-
C) caspase-14, (D-F) hCG, (G-I) KLF4 and (J-L) cytokeratin-18. * = P < 0.05 versus controls at the same time point.
Figure 1Page 4 of 10
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data in combination suggest a role for KLF4 in trophoblast
differentiation.
The intermediate filament protein cytokeratin-18 (K18) is
consistently expressed in BeWo cells. However, after 48
hours of Forskolin treatment corresponding with the
onset of morphological differentiation, its transcription
was significantly elevated relative to time-matched con-
trols (P < 0.05) (Fig. 1J). K18 protein expression remained
stable throughout biochemical differentiation; however,
by the onset of morphological differentiation at 72 hours,
K18 expression was significantly increased (Figs 1K, L).
This suggests that K18 is involved in the cell fusion proc-
ess. Indeed, the elevated mRNA levels after 48 hours of
Forskolin treatment (Fig. 1J) immediately precedes the
increase in protein levels (Fig 1K, L). Therefore the
increased transcription of K18 follows through into
increased translation with morphological differentiation.
Consequently, K18 is modulated by morphological tro-
phoblast differentiation.
In the epidermis caspase-14 cleaves and activates profilag-
grin. However, while it was present in the epidermal
HaCaT cells, no filaggrin mRNA was detectable in either
the human placenta or BeWo cell line (See Additional file
1). Therefore, caspase-14 must target discrete cellular
pathways in the human trophoblast.
Validation of RNAi
Real Time PCR revealed that caspase-14 mRNA was signif-
icantly reduced in DMSO treated BeWo cells at all times
compared with those treated with the Mock siRNA (P <
0.05) (Fig. 2A). Furthermore, mRNA expression was
reduced at all times following co-incubation with Forsko-
lin (Fig. 2D). Thus, caspase-14 is effectively suppressed in
the BeWo cell line following treatment with transcript-
specific siRNA.
The successful reduction of caspase-14 protein was quan-
tified using Western blot analysis. Caspase-14 levels were
significantly reduced after both 48 and 72 hours of treat-
ment with siRNA in control and differentiating BeWo cells
(P < 0.05) (Figs 2B, E). Furthermore, caspase-14 protein in
both groups was suppressed to a level approaching signif-
icance after 24 hours of treatment (P < 0.1). Therefore,
caspase-14 is successfully suppressed in both differentiat-
ing and non-differentiating BeWo cells.
As caspase-14 mRNA and protein were similarly sup-
pressed in both control and differentiating BeWo cells
(Fig. 2), the addition of Forskolin did not interfere with
the efficacy of caspase-14 siRNA. Therefore, caspase-14 is
significantly suppressed at both the mRNA and protein
levels in both control and differentiating BeWo cells.
RNAi in control BeWo cells
Following 24 and 48 hours of culture in the absence of
caspase-14, the quantity of β-hCG mRNA was elevated
(Fig. 3A). This indicates that transcription of β-hCG is
negatively regulated by the activity of caspase-14. There-
fore, caspase-14 is biologically involved in the regulation
of placental hormone production in control BeWo cells,
and may act as a switch for repressing hCG production in
Suppression of Caspase-14Figu  2
Suppression of Caspase-14. Validation of the success of RNAi in suppressing caspase-14 in (A-C) control BeWo cells and 
(D-F) during differentiation. * = P < 0.05 versus controls at the same time point.
Figure 2Page 5 of 10
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trophoblast differentiation, caspase-14 may be involved
in the suppression of this process.
However, it was only after 72 hours of incubation with
caspase-14 siRNA that hCG protein was significantly ele-
vated in control BeWo cells (P < 0.05) (Figs 3B, C). Due to
the high seeding rate at the commencement of treatment,
BeWo cells were confluent after 72 hours in vitro. Since
BeWo cells grow as monolayers, confluence may induce
contact inhibition of the cell cycle. That β-hCG protein
was increased in BeWo cells at this point after caspase-14
knock-down suggests that caspase-14 suppresses hCG
production after cell cycle withdrawal in the trophoblast.
KLF4 acts as a transcription factor to suppress the synthe-
sis of cyclin D2, thereby inducing cell cycle arrest at the
G1/S phase boundary. Transcription of KLF4 is increased
in BeWo cells after both 24 and 48 hours of treatment
with caspase-14 specific siRNA (P < 0.05) (Fig. 3D). This
suggests that caspase-14 inhibits KLF4-mediated cell cycle
suppression in BeWo cells. However, KLF4 translation was
not found to be significantly altered after either 24 or 72
hours of treatment but, rather, reduced after 48 hours (P
< 0.05) (Figs 3E, F). As with data from differentiating
BeWo cells, mRNA and protein data for KLF4 do not cor-
relate with one another. This indicates the presence of
post-transcriptional regulation of KLF4 activity in the
BeWo cell line.
By suppressing caspase-14, the transcription of K18 was
significantly increased after 24 and 48 hours (P < 0.05)
(Fig. 3G). This indicates that caspase-14 is involved in
inhibiting the synthesis of K18 in the BeWo cell line. No
increase was found at the protein level until after 72 hours
(P < 0.05), although after 48 hours it was approaching sig-
nificance (P = 0.06) (Figs 3H, I). This suggests that K18
translation requires a long time period for completion.
Alternatively, post-transcriptional mechanisms may
inhibit the translation of the mRNA until such time as
intermediate filament and cytoskeletal modulation is
required.
Caspase-14 modulates trophoblast gene expressionFigure 3
Caspase-14 modulates trophoblast gene expression. The effect of caspase-14 siRNA on the expression of (A-C) hCG, 
(D-F) KLF4 and (G-I) cytokeratin-18 in DMSO-treated BeWo cells. * = P < 0.05 versus Mock siRNA treated controls at the 
same time point.
Figure 3Page 6 of 10
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In support of data for control BeWo cells (Fig. 3), β-hCG
mRNA was increased following the suppression of cas-
pase-14 24 hours after the addition of Forskolin (Fig. 4A),
confirming a role for caspase-14 in the regulation of hCG
synthesis in the homeostatic and differentiating trophob-
last. As hCG production is greatly elevated during differ-
entiation, but with no increase in β-hCG mRNA after 48
hours of siRNA treatment, suggests that there may be a
threshold to its production as the level is much higher in
these cells than in the non-Forskolin treated cells (>10-
fold). This may explain why there is a less marked increase
in β-hCG after siRNA in differentiating BeWo cells com-
pared to DMSO treated controls (Figs 3A, 4A).
Nevertheless, β-hCG protein production was increased 48
and 72 hours after Forskolin treatment (P < 0.05) (Figs 4B,
C). However, β-hCG protein levels were significantly
reduced 24 hours after treatment, representing an interest-
ing regulatory mechanism of hCG production by caspase-
14 in the biochemically differentiating trophoblast.
Indeed, this may indicate that caspase-14 does not directly
affect hCG production but, rather, acts as an upstream
modulator of hormone production.
The expression of KLF4 mRNA in differentiating BeWo
cells was not significantly affected by the loss of caspase-
14 (P >0.05) (Fig. 4D). However, expression of its protein
was significantly reduced 24 hours after Forskolin treat-
ment (P < 0.05) (Figs 4E, F). Therefore, caspase-14 only
influences KLF4 in differentiated BeWo cells at 24 hours.
As KLF4 suppresses proliferation, reduced protein levels
indicate that differentiating BeWo cells may be escaping
cell cycle withdrawal in the absence of caspase-14, thereby
enhancing proliferation. However, this is in conflict with
data pertaining to differentiation which suggest that dif-
ferentiation is enhanced in the absence of caspase-14 (Figs
3A-C; 4A-C). Therefore, a complex mechanism exists in
the interaction between caspase-14 and KLF4.
After 24 hours of Forskolin treatment, K18 mRNA levels
were increased in response to Forskolin in the absence of
Caspase-14 modulates trophoblast gene expression during differentiationFigure 4
Caspase-14 modulates trophoblast gene expression during differentiation. The effect of caspase-14 siRNA on the 
expression of (A-C) hCG, (D-F) KLF4, and (G-I) cytokeratin-18 in Forskolin-treated BeWo cells. * = P < 0.05 versus Mock 
siRNA treated controls at the same time point.
Figure 4Page 7 of 10
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hours K18 expression was approaching significance (P =
0.06). Therefore, the lack of caspase-14 during differenti-
ation leads to the increased transcription of this key
cytoskeletal component.
Interestingly, the K18 protein was significantly reduced
during early BeWo differentiation (P < 0.05) (Figs 4H, I).
Moreover, K18 protein was significantly elevated 48 hours
after Forskolin treatment in BeWo cells deficient in cas-
pase-14, indicating a period of lag between transcription
and translation lasting 24 hours. However, by the time
morphological differentiation was occurring (72 hours)
expression of K18 was unchanged (P < 0.05), suggesting
that caspase-14 does not influence K18 production in fus-
ing BeWo cells. Therefore, caspase-14 modulates K18 pro-
duction during biochemical differentiation of BeWo cells
in preparation for cytoskeletal rearrangements accompa-
nying morphological differentiation.
Discussion
Induction of BeWo cell differentiation results in reduced
caspase-14 expression at both the transcriptional and
translational levels (Fig. 1). As the direction of change is
the opposite of that observed during keratinocyte differ-
entiation [3,5,23], the mechanism of caspase-14 activa-
tion and subsequent function is likely to be different in
the trophoblast. Indeed, the cleaved subunits of caspase-
14 were not detected in BeWo cell extracts, and the epider-
mal target of caspase-14 activity, profilaggrin, is absent
from the human trophoblast and BeWo cell line (See
Additional file 1), confirming a disparity in caspase-14
function between the two tissues.
The reduced expression of caspase-14 throughout BeWo
cell differentiation suggests a role suppressing trophoblast
differentiation. Analysis of this prospect was conducted by
investigating the effect of caspase-14 suppression on hCG,
which is commonly used as a marker of trophoblast dif-
ferentiation and pregnancy. The production of hCG was
elevated following caspase-14 suppression (Figs 3A-C; 4A-
C), confirming a role for caspase-14 in inhibition of tro-
phoblast differentiation.
The cell cycle inhibitor KLF4 contains a binding motif
consistent with that identified for caspase-14 [13]. Fur-
thermore, KLF4 is involved in the maintenance of the
human placenta [14,15], while mouse knock-out models
of caspase-14 and KLF4 display remarkably similar epider-
mal phenotypes [6,9,25]. However, the pattern of KLF4
mRNA expression in BeWo cells is the opposite of that for
caspase-14, increasing significantly throughout differenti-
ation (Fig. 1G). As KLF4 is a cell cycle suppressor, this
indicates that it is involved in the cell cycle withdrawal
required for differentiation, suggesting an antagonism
between KLF4 and caspase-14 whereby KLF4 promotes
while caspase-14 suppresses trophoblast differentiation.
Indeed, suppression of caspase-14 results in increased
KLF4 mRNA expression in control BeWo cells (Fig. 3D).
As inhibition of caspase-14 results in increased hCG pro-
duction, indicating enhanced differentiation (Figs 3A-C,
4A-C), this suggests that KLF4 is involved in cell cycle
withdrawal resulting in enhanced differentiation. How-
ever, despite all of this, there is no concrete evidence for
direct interaction between the two, so further examination
of the potential relationship between caspase-14 and
KLF4 is required.
K18 mRNA and protein were elevated after 48 and 72
hours of Forskolin treatment (Figs 1J-L), correlating with
the onset of morphological BeWo cell differentiation.
Thus, elevated K18 parallels with the onset of fusion, sup-
porting a significant rearrangement of the intermediate
filament cytoskeleton in preparation for intercellular
fusion of the trophoblast. That K18 is further increased
following caspase-14 suppression (Figs 3G-I, 4G-I) indi-
cates that morphological differentiation is accelerated in
the absence of caspase-14. This provides further evidence
of a role for caspase-14 in inhibiting trophoblast differen-
tiation. Furthermore, as the cytokeratin architecture is
indirectly affected by caspase-14 activity in keratinocytes
[6], it is attractive to postulate that K18 arrangement is a
downstream target of caspase-14 during the morphologi-
cal differentiation of the trophoblast.
Interestingly, the transcription of the genes examined in
this study appears to be more sensitive to the suppression
of caspase-14 than their subsequent proteins (Figs 3, 4).
While this may be indicative of the natural delay between
transcription and translation, it may also suggest that cas-
pase-14 is involved in suppression of translation within
the trophoblast. However, discrepancies between tran-
scription and translation of genes in BeWo cells were also
observed in the presence of caspase-14 (Fig. 1), indicating
that this is a feature of the trophoblast, not caspase-14.
On the face of it, caspase-14 is a promiscuous molecule.
Its suppression seems to affect a multitude of signalling
pathways including hormonal (hCG), cell cycle (KLF4)
and cytoskeletal (K-18). However, each factor is also
implicated in trophoblast differentiation. Synthesis and
production of β-hCG and KLF4 is significantly increased
throughout BeWo cell differentiation. Moreover, K-18
synthesis and production is increased across the crucial
period between 48 and 72 hours when morphological dif-
ferentiation is induced.
That caspase-14 is significantly reduced across BeWo cell
differentiation indicates that it is somehow involved inPage 8 of 10
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Indeed, data presented here indicate that caspase-14 does
indeed suppress BeWo cell differentiation both in the bio-
chemical (24-48 hours) and morphological (48-72
hours) phases. This suggests an intriguing function for
caspase-14 as a checkpoint for adequate BeWo cell differ-
entiation. Future studies into the question of whether cas-
pase-14 regulates the extent of differentiation and acts as
an essential checkpoint to prevent uncontrolled differen-
tiation may provide further insight into its function in the
human placenta.
In this study there are some differences with our previous
results which showed increased caspase-14 mRNA expres-
sion during differentiation. However in that study there
was a concomitant decline in caspase-14 mRNA expres-
sion across the time-course of the study, an effect which
was not observed in the present study. Importantly, data
obtained from the RNAi experiments are consistent with
caspase-14 expression being reduced during differentia-
tion. Furthermore, the differences in caspase-14 protein
expression across BeWo cell differentiation between our
current and previous studies may be due to the antibody
used for its detection. The present study utilised the anti-
body validated and extensively used to examine caspase-
14 function in the epidermis, bringing our data in to line
with previous research conducted into caspase-14 biol-
ogy. Therefore data presented here are more detailed and
thought to be more representative of the actual role of cas-
pase-14.
The target of caspase-14 activity in the epidermis- profilag-
grin- is not present in either the human placenta or BeWo
cell line (See Additional file 1). Therefore, other targets
must exist for caspase-14 in the human placenta. Cru-
cially, processing of mature caspase-14 into its active sub-
units, as evidenced in the epidermis, is absent from BeWo
cells. The nature of caspase-14 activity within the trophob-
last is therefore uncertain. Despite the significant
advances in the understanding of caspase-14 biology that
have been made in the current study, its immediate activ-
ity and target(s) in the trophoblast remain elusive.
Microarray technology could be used in conjunction with
RNAi to reveal genes and pathways directly affected by
caspase-14 in the differentiating trophoblast. hCG inhib-
its the activation of AP-1 transcription factors [26], the lat-
ter of which also regulate the transcription of caspase-14
[27]. Indeed the pro-mitotic c-Jun is restricted to the pro-
liferative cytotrophoblast, while the quiescence-maintain-
ing JunD is confined to the syncytium [28]. Thus, c-Jun
may stimulate and JunD inhibit caspase-14 transcription
in the trophoblast. Further studies involving RNAi against
c-Jun and JunD may reveal the mechanisms controlling
caspase-14-mediated inhibition of differentiation in the
trophoblast. Thereby the molecular triggers dictating cas-
pase-14 activity may be revealed.
Conclusion
This article reveals a novel function for the protease cas-
pase-14 in modulating the differentiation of the human
trophoblast. As inappropriate trophoblast differentiation
is a potential cause of the aetiology of preeclampsia and
poor fetal growth, further investigation into the formation
of the maternal-fetal barrier has important implications
for the understanding of diseases in which differentiation
may be disrupted. We contend that inappropriate caspase-
14 activity during trophoblast differentiation may be
involved in the onset of preeclampsia. Further investiga-
tion is ongoing to explore this possibility.
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